Management of melanoma: A European perspective

Lex Eggermont; C Voit

doi:10.1016/j.soc.2008.02.004

Management of melanoma: A European perspective

Lex Eggermont
, C Voit

Surgery

Research output: Contribution to journal › Article › Academic

9 Citations (Scopus)

Abstract

Clinical management of melanoma requires insight into the utility of adjuvant surgical and systemic therapy options. This article discusses the evidence from randomized, controlled trials of adjuvant surgical therapy, sentinel node biopsy, and surveillance of regional lymph node basins by ultrasound. Ultrasound also can be used to identify metastasis in the sentinel node to avoid unnecessary sentinel node biopsies. It describes the experience with chemotherapy, immunostimulants, and vaccines, which have failed as adjuvants in stage II-III disease. Interferon has a consistent effect on relapse-free survival, although it does not have a significant benefit for overall survival.

Original language	Undefined/Unknown
Pages (from-to)	635-+
Journal	Surgical Oncology Clinics of North America
Volume	17
Issue number	3
DOIs	https://doi.org/10.1016/j.soc.2008.02.004
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-47-11

Access to Document

10.1016/j.soc.2008.02.004

http://hdl.handle.net/1765/30139

Cite this

@article{5c19b31eb019418082dcfdf76dbc3f46,

title = "Management of melanoma: A European perspective",

abstract = "Clinical management of melanoma requires insight into the utility of adjuvant surgical and systemic therapy options. This article discusses the evidence from randomized, controlled trials of adjuvant surgical therapy, sentinel node biopsy, and surveillance of regional lymph node basins by ultrasound. Ultrasound also can be used to identify metastasis in the sentinel node to avoid unnecessary sentinel node biopsies. It describes the experience with chemotherapy, immunostimulants, and vaccines, which have failed as adjuvants in stage II-III disease. Interferon has a consistent effect on relapse-free survival, although it does not have a significant benefit for overall survival.",

author = "Lex Eggermont and C Voit",

year = "2008",

doi = "10.1016/j.soc.2008.02.004",

language = "Undefined/Unknown",

volume = "17",

pages = "635--+",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

number = "3",

}

TY - JOUR

T1 - Management of melanoma: A European perspective

AU - Eggermont, Lex

AU - Voit, C

PY - 2008

Y1 - 2008

N2 - Clinical management of melanoma requires insight into the utility of adjuvant surgical and systemic therapy options. This article discusses the evidence from randomized, controlled trials of adjuvant surgical therapy, sentinel node biopsy, and surveillance of regional lymph node basins by ultrasound. Ultrasound also can be used to identify metastasis in the sentinel node to avoid unnecessary sentinel node biopsies. It describes the experience with chemotherapy, immunostimulants, and vaccines, which have failed as adjuvants in stage II-III disease. Interferon has a consistent effect on relapse-free survival, although it does not have a significant benefit for overall survival.

AB - Clinical management of melanoma requires insight into the utility of adjuvant surgical and systemic therapy options. This article discusses the evidence from randomized, controlled trials of adjuvant surgical therapy, sentinel node biopsy, and surveillance of regional lymph node basins by ultrasound. Ultrasound also can be used to identify metastasis in the sentinel node to avoid unnecessary sentinel node biopsies. It describes the experience with chemotherapy, immunostimulants, and vaccines, which have failed as adjuvants in stage II-III disease. Interferon has a consistent effect on relapse-free survival, although it does not have a significant benefit for overall survival.

U2 - 10.1016/j.soc.2008.02.004

DO - 10.1016/j.soc.2008.02.004

M3 - Article

C2 - 18486887

SN - 1055-3207

VL - 17

SP - 635-+

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 3

ER -